CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today t…
Author: Business Wire
Global Corneal Implants Market Report 2022: Increasing Prevalence of Corneal Disorders Drives Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Corneal Implants Market Size, Share & Trends Analysis Report by Type (Human Cornea, Synthetic), by Application (Keratoconus, Fuchs Dystrophy), by End-user (Hospital, ASC), by Surgery Method, and Segment Forecasts, 2022…
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that interim Phase 2 data eva…
VSP Vision and PECAA Join Forces; Expand Commitment to Independent Eye Care Professionals
RANCHO CORDOVA, Calif. & BOCA RATON, Fla.–(BUSINESS WIRE)–The industry’s two largest supporters of independent eye care professionals are uniting to ensure the continued success and growth of private practice. Today, VSP Vision™ announced the acquisi…
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced new data on the key drivers of Thyroid Eye Disease (TED) at the American Academy of Ophthalmology (AAO) 2022.
CXL Ophthalmics Announces $32 Million Series A Investment Round Led by AXA IM Alts, Through its Global Health Private Equity Strategy
SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics today announced it has raised a $32 million Series A funding round led by AXA IM Alts plus a syndicate of individual investors.
EyeSouth Partners, the largest comprehensive ophthalmology platform in North America, continues its accelerating growth with a new Capital Partner, Olympus Partners
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”), the largest comprehensive ophthalmology platform in North America, is proud to announce and welcome its new private equity firm investor, Olympus Partners. Founded in 1988, Olym…
Shore Capital Partners Announces Sale of EyeSouth Partners
CHICAGO–(BUSINESS WIRE)–Shore Capital Partners, a private equity firm focused on microcap investing, announces the sale of EyeSouth Partners to Olympus Partners.
Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgery
CHICAGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy.
CXL Ophthalmics Publishes Results of EpiSmart® Cross-Linking Phase 2 Clinical Trial for Keratoconus in Cornea
SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics today published results of the EpiSmart Cross-linking Phase 2 study for Keratoconus in Cornea.
Global Intraocular Lens Market Report to 2031 – Players Include Alcon, Bausch Health, Carl Zeiss Meditech and Hoya – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Intraocular Lens Market By Type, By Material, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering. The intraocular lens market was valued $3…
InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, its NLRP3 Inflammasome-targeting Program in Retinal and Kidney Disease
TAMPA, Fla.–(BUSINESS WIRE)–InflammX Therapeutics, Inc. (InflammX), a privately held biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Amendment to U.S. Food and Drug Administration (FDA), to enable the co…
Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Ac…
EyeCare Partners Ophthalmologists to Present New Data at the 2022 American Academy of Ophthalmology (AAO) Meeting
ST. LOUIS–(BUSINESS WIRE)–EyeCare Partners ophthalmologists to present new data at the 2022 American Academy of Ophthalmology (AAO) Meeting.
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
LEDGEWOOD, N.J.–(BUSINESS WIRE)—- $HROW–ImprimisRx, America’s #1 Ophthalmic Pharmacy™, today announced the availability of Fortisite™, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%. Compounded topical a…
ModMed® Reveals Latest Digital Tools Aimed at Modernizing the Ophthalmology Patient Experience
BOCA RATON, Fla.–(BUSINESS WIRE)–According to a new study1 commissioned by ModMed®, many factors contribute to making an impression on a patient, the first of which is often when a patient reads an online review. In fact, 74% of patients place import…
EyeSouth Partners Affiliates With Arbor Centers for EyeCare and Chicago Eye Institute, Representing Its 32nd and 33rd Affiliations and Initial Entry Into Illinois
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed affiliations with Arbor Centers for EyeCare and Chicago Eye Institute, leading ophthalmic practices in Chicagoland for decades, which…
Ora, Inc. Launches the Ora EyecupTM, a Revolutionary Ophthalmic Research Technology at Eyecelerator 2022
BOSTON–(BUSINESS WIRE)–Ora, Inc., the world’s leading ophthalmology clinical research firm, has formally launched a revolutionary mobile research platform, Ora EyeCupTM, which promises to transform patient data capture through high-resolution imaging…
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets
SEATTLE–(BUSINESS WIRE)– #presbyopia–Visus Therapeutics Inc. expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics, Inc.